As critical transcription factors for lymphopoiesis and lymphoid malignancies, degradation of IKZF1 and IKZF3 by the CRL4CRBN E3 ubiquitin ligase complex mediates the anti-myeloma effect of lenalidomide [57,58]. Here, IKZF1 is linked to plasma cell myeloma.